Loading
companiesCompany
4SC
4SC is a listed German biotechnology company founded in 1997 in Planegg-Martinsried, near Munich. It applied to the EMA for its HDAC inhibitor resminostat (Kinselby) in advanced mycosis fungoides and Sézary syndrome and received a negative opinion in May 2025.
Also called: 4SC AG4Sc AG
Overview
4SC is a public company based in Martinsried, Germany, founded in 1997 (Wikidata Q238181, which also gives its website). The EMA product page for Kinselby (resminostat, orphan designation) names 4Sc AG as the marketing authorisation applicant; the CHMP adopted its opinion on 22 May 2025 and the opinion status is negative, so the product is not authorised. It sponsors no trial recorded in OnCo.
Headquarters
Planegg-Martinsried, DE
Scorecard
All companies#366of 1244 companies, score 10
- targets +2
- modalities +2
- 24-month regulatory events +2
- registry trials +4
0 approved, 0 in phase 3, 0 earlier, 1 targets, 5 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
1997
Small-molecule HDAC inhibitor
Resminostat · Kinselby
Resminostat is an oral drug of the HDAC inhibitor class, proposed for advanced mycosis fungoides and Sézary syndrome, two cutaneous T-cell lymphomas. Europe's medicines committee said no to it in May 2025, so it is not authorised.
Similar pages
- TreatmentRomidepsin
Shares Histone deacetylases (HDAC), Resminostat, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- TreatmentVorinostat
Shares Histone deacetylases (HDAC), Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- TreatmentBelinostat
Shares Histone deacetylases (HDAC), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- CancerSezary syndrome
Shares Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS), Resminostat, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).